" class="no-js "lang="en-US"> Cannabics Pharmaceuticals - Medtech Alert
Thursday, May 07, 2026

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Cannabics Pharmaceuticals | Pharmtech Focus

Cannabics Pharmaceuticals

About Cannabics Pharmaceuticals

Cannabics Pharmaceuticals

Cannabics Pharmaceuticals is a publicly traded company (CNBX: OTCQB) and developer of the world’s first cannabinoid-based antitumor drug candidate for the treatment of colorectal cancer based on the company’s novel and proprietary formulation Cannabics™️ RCC-33.

Related Story

Drug Development

 Cannabics Pharmaceuticals Launches a New Research Program to develop a Melanoma Treatment Drug Candidate for FDA Approval Track | Pharmtech Focus

Cannabics Pharmaceuticals Launches a New Research Program to Develop a Melanoma Treatment Drug Candidate for FDA Approval Track

April 27 2021

Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, […]